MX2017006491A - Composiciones y métodos para la modulación de la actividad at2r. - Google Patents
Composiciones y métodos para la modulación de la actividad at2r.Info
- Publication number
- MX2017006491A MX2017006491A MX2017006491A MX2017006491A MX2017006491A MX 2017006491 A MX2017006491 A MX 2017006491A MX 2017006491 A MX2017006491 A MX 2017006491A MX 2017006491 A MX2017006491 A MX 2017006491A MX 2017006491 A MX2017006491 A MX 2017006491A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- at2r
- activity
- compositions
- modulating
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 101150059573 AGTR1 gene Proteins 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
Abstract
Se divulgan nuevos agonistas de polipéptido de AT2R, así como composiciones farmacéuticas que comprenden los agonistas, métodos de su uso en el tratamiento de enfermedades, padecimientos o trastornos caracterizados por la actividad de AT2R insuficiente o la actividad de AT1R excesiva, y métodos de su uso como reactivos de laboratorio para propósitos de investigación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462081839P | 2014-11-19 | 2014-11-19 | |
PCT/US2015/061597 WO2016081733A2 (en) | 2014-11-19 | 2015-11-19 | Compositions and methods for modulating at2r activity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017006491A true MX2017006491A (es) | 2018-02-13 |
Family
ID=56014682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017006491A MX2017006491A (es) | 2014-11-19 | 2015-11-19 | Composiciones y métodos para la modulación de la actividad at2r. |
Country Status (10)
Country | Link |
---|---|
US (2) | US10105411B2 (es) |
EP (1) | EP3220940B1 (es) |
JP (2) | JP6934814B2 (es) |
AU (2) | AU2015349863B2 (es) |
CA (1) | CA2968053A1 (es) |
ES (1) | ES2892957T3 (es) |
IL (1) | IL252191B (es) |
MX (1) | MX2017006491A (es) |
RU (1) | RU2721241C2 (es) |
WO (1) | WO2016081733A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2968053A1 (en) | 2014-11-19 | 2016-05-26 | Novopyxis Inc. | Compositions and methods for modulating at2r activity |
US20210238229A1 (en) * | 2018-06-14 | 2021-08-05 | University College Cork - National University Of Ireland, Cork | Peptide for disease treatment |
WO2020000469A1 (zh) * | 2018-06-29 | 2020-01-02 | 深圳市博奥康生物科技有限公司 | 促进 at2r 蛋白过表达的重组载体及其构建方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPO981397A0 (en) * | 1997-10-15 | 1997-11-06 | Garvan Institute Of Medical Research | Novel npy family member |
US7173011B2 (en) * | 2000-11-20 | 2007-02-06 | University Of Southern California | Radiation therapy methods |
US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
WO2006073772A1 (en) * | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
US8362325B2 (en) * | 2007-10-03 | 2013-01-29 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics |
US9029636B2 (en) * | 2008-02-05 | 2015-05-12 | Monsanto Technology Llc | Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits |
MX2011005965A (es) * | 2008-12-05 | 2011-09-01 | Angiochem Inc | Conjugados de leptina y de análogos de leptina y sus usos de los mismos. |
FR2943346B1 (fr) * | 2009-03-19 | 2011-05-06 | Univ Paris Curie | Peptides modulant l'activite de l'igf-1 et leurs applications |
WO2010138555A2 (en) * | 2009-05-26 | 2010-12-02 | University Of Florida Research Foundation, Inc. | Small peptide expression system in mammalian cells |
US8835471B2 (en) * | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
EP2455388A1 (en) * | 2010-11-23 | 2012-05-23 | LanthioPep B.V. | Novel angiotensin type 2 (AT2) receptor agonists and uses thereof. |
RU2472471C1 (ru) * | 2011-11-24 | 2013-01-20 | Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения и социального развития Российской Федерации | Способ снижения внутриглазного давления |
US20150119329A1 (en) * | 2012-04-16 | 2015-04-30 | New York University | Modulation of angiotensin ii receptors for the prevention and treatment of malaria cerebral |
CA2968053A1 (en) | 2014-11-19 | 2016-05-26 | Novopyxis Inc. | Compositions and methods for modulating at2r activity |
-
2015
- 2015-11-19 CA CA2968053A patent/CA2968053A1/en active Pending
- 2015-11-19 EP EP15860292.0A patent/EP3220940B1/en active Active
- 2015-11-19 AU AU2015349863A patent/AU2015349863B2/en not_active Ceased
- 2015-11-19 WO PCT/US2015/061597 patent/WO2016081733A2/en active Application Filing
- 2015-11-19 JP JP2017545867A patent/JP6934814B2/ja active Active
- 2015-11-19 RU RU2017121091A patent/RU2721241C2/ru active
- 2015-11-19 MX MX2017006491A patent/MX2017006491A/es unknown
- 2015-11-19 ES ES15860292T patent/ES2892957T3/es active Active
-
2017
- 2017-05-09 IL IL252191A patent/IL252191B/en unknown
- 2017-05-15 US US15/595,517 patent/US10105411B2/en active Active
-
2018
- 2018-09-13 US US16/130,820 patent/US10675324B2/en active Active
-
2021
- 2021-06-01 JP JP2021092413A patent/JP2021130704A/ja active Pending
- 2021-08-26 AU AU2021221858A patent/AU2021221858A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10675324B2 (en) | 2020-06-09 |
JP2021130704A (ja) | 2021-09-09 |
JP2017536415A (ja) | 2017-12-07 |
ES2892957T3 (es) | 2022-02-07 |
RU2721241C2 (ru) | 2020-05-18 |
US20170304390A1 (en) | 2017-10-26 |
US20190000916A1 (en) | 2019-01-03 |
EP3220940B1 (en) | 2021-07-21 |
EP3220940A2 (en) | 2017-09-27 |
AU2015349863B2 (en) | 2021-09-09 |
US10105411B2 (en) | 2018-10-23 |
EP3220940A4 (en) | 2018-10-03 |
RU2017121091A (ru) | 2018-12-19 |
JP6934814B2 (ja) | 2021-09-15 |
CA2968053A1 (en) | 2016-05-26 |
IL252191B (en) | 2022-03-01 |
AU2021221858A1 (en) | 2021-09-23 |
AU2015349863A1 (en) | 2017-06-01 |
IL252191A0 (en) | 2017-07-31 |
WO2016081733A3 (en) | 2016-07-28 |
RU2017121091A3 (es) | 2019-06-05 |
WO2016081733A2 (en) | 2016-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501809A1 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
PH12016500582A1 (en) | Heterocyclic compounds and uses thereof | |
EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
SG10201903823QA (en) | Methods and compositions relating to microbial treatment and diagnosis of disorders | |
MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
NZ731789A (en) | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
MY187540A (en) | Compounds active towards bromodomains | |
CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
EA201692109A1 (ru) | Варианты антител к фактору d и их применение | |
MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
WO2015171610A3 (en) | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease | |
NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
MX2017009417A (es) | Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas. | |
WO2015171558A3 (en) | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE | |
MY199091A (en) | Therapeutic compounds | |
NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
MX2020000135A (es) | Nuevos compuestos de quinolinona. | |
SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. |